Advertisement
GRFS vs NVS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Hold and NVS is a Buy.
GRFS's RSI Oscillator recovers from oversold territory
The RSI Oscillator for GRFS moved out of oversold territory on September 24, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 22 of the 31 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on GRFS as a result. In 58 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for GRFS just turned positive on October 02, 2026. Looking at past instances where GRFS's MACD turned positive, the stock continued to rise in 26 of 46 cases over the following month. The odds of a continued upward trend are 57%.
Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in 190 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 64 cases where GRFS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
GRFS moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
GRFS broke above its upper Bollinger Band on October 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRFS entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.914) is normal, around the industry mean (-3.019). P/E Ratio (11.288) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (5.738). Dividend Yield (0.047) settles around the average of (0.041) among similar stocks. GRFS's P/S Ratio (0.592) is slightly lower than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
NVS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 44 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +1.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 184 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.043) is normal, around the industry mean (-3.019). P/E Ratio (23.078) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.123) as compared to the industry average of (0.041). P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
GRFS | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 6 | |
SMR RATING 1..100 | 76 | 33 | |
PRICE GROWTH RATING 1..100 | 58 | 44 | |
P/E GROWTH RATING 1..100 | 83 | 20 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GRFS's Valuation (9) in the Pharmaceuticals Major industry is in the same range as NVS (9). This means that GRFS’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for GRFS (100). This means that NVS’s stock grew significantly faster than GRFS’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for GRFS (76). This means that NVS’s stock grew somewhat faster than GRFS’s over the last 12 months.
NVS's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as GRFS (58). This means that NVS’s stock grew similarly to GRFS’s over the last 12 months.
NVS's P/E Growth Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for GRFS (83). This means that NVS’s stock grew somewhat faster than GRFS’s over the last 12 months.
| GRFS | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 41% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 40% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 51% |
| Advances ODDS (%) | 7 days ago 69% | 1 day ago 55% |
| Declines ODDS (%) | 1 day ago 76% | 17 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 35% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GRFS’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- GRFS’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GRFS’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- GRFS’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 5 bullish, 5 bearish.
Price Growth
GRFS (@Pharmaceuticals: Major) experienced а +3.59% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.
Reported Earning Dates
GRFS is expected to report earnings on Nov 10, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GRFS and
Correlation & Price change
A.I.dvisor tells us that GRFS and SNY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and SNY's prices will move in lockstep.
| Ticker / NAME | Correlation To GRFS | 1D Price Change % | ||
|---|---|---|---|---|
| GRFS | 100% | -0.67% | ||
| SNY - GRFS | 29% Poorly correlated | +2.42% | ||
| GSK - GRFS | 28% Poorly correlated | +2.38% | ||
| GILD - GRFS | 28% Poorly correlated | +2.36% | ||
| NVS - GRFS | 28% Poorly correlated | +1.52% | ||
| BMY - GRFS | 27% Poorly correlated | +3.08% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FGSM | 34.15 | -0.18 | -0.53% |
| Frontier Asset Global Small-Cap Equity ETF | |||
| IPKW | 59.67 | -0.37 | -0.61% |
| Invesco International BuyBack Achievers ETF (IPKW) | |||
| DFE | 73.85 | -0.68 | -0.91% |
| WisdomTree Europe SmallCap Dividend Fund (DFE) | |||
| DEM | 53.87 | -0.92 | -1.68% |
| WisdomTree Emerging Markets High Dividend Fund (DEM) | |||
| POEL | 3.60 | -0.50 | -12.20% |
| Defiance Daily Target 2X Long POET ETF | |||